Publication: Thymidylate synthase predicts for
clinical outcome in invasive breast cancer
Authors
Yu, Z. ; Sun, J. ; Zhen, J. ; Zhang, Q. ; Yang, Q.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Thymidylate synthase (TS) is a major target
of 5-fluorouracil (5-FU) and dihydropyrimidine
dehydrogenase (DPD) is a rate-limiting enzyme in the
degradation of 5-FU. Whether TS or DPD could be used
as valuable parameters for 5-FU sensitivity in clinical
patients are largely unknown. We analyzed TS and DPD
expression in breast carcinomas to evaluate the
clinicopathological significance of these enzymes in
patients with invasive breast cancer receiving 5-FUbased
chemotherapy. A total of 197 patients with
invasive ductal carcinoma were included in our study.
Both the TS and DPD expression were analyzed using
immunohistochemical method for all the surgical
samples. Sixty-three out of 197 (31.97%) patients are
positive for TS expression, and 77 out of 197 (39.09%)
patients are positive for DPD expression. TS expression
was not correlated with DPD expression. Patients with
TS-positivity had aggressive phenotype including large
tumor size, low differentiation and nodal metastasis.
DPD expression is not related with phenotype or
prognosis. Multivariate analysis demonstrated that TS
expression was an independent prognostic factor for
both disease-free and overall survival. The current study
demonstrated that TS but not DPD expression was
associated with both progression and prognosis in breast
cancer receiving 5-FU-based chemotherapy. TS
expression in the primary tumor might be useful as a
predictive parameter for the efficacy of 5-FU-based
chemotherapy for breast cancer.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.